Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

524 Views

Poster Session: Adult Vaccines

121 - Safety, Tolerability, and Pertussis Immunogenicity Findings From a Randomized, Participant-Blinded, Active-Controlled, Dose-Escalating, Phase 1 Trial of a Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018 CpG Adjuvanted) Compared With Boostrix in Healthy Adults Aged 18 to 22 Years

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Robert Janssen, MD

Chief Medical Officer
Dynavax Technologies Corporation
Emeryville, California, United States

Co-Author(s)

AM

Anthony McGirr, MBBS

Northern Beaches Clinical Research
Brookvale, New South Wales, Australia
FN

Fiona Napier-Flood, BSc, PhD, MBBS, DCH, FRACGP

Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
AL

Amber Leah, BSc Chem (Hons) MBBS DCH Clin Dip Pall Med FRACGP

Paratus Clinical Research Canberra
Bruce, Australian Capital Territory, Australia
TN

Terry Nolan, MD, PhD

The Peter Doherty Institute for Infection and Immunity, Murdoch Children’s Research Institute
Melbourne, Victoria, Australia
PR

Peter Richmond, MBBS

University of Western Australia School of Medicine, Perth’s Children Hospital
Nedlands, Western Australia, Australia
TB

Tammy Boyce, MEd

Dynavax Technologies Corporation
Emeryville, California, United States
FX

Fang Xie, PhD

Dynavax Technologies Corporation
Emeryville, California, United States
OG

Olivier Godeaux, MD, MPH

Dynavax Technologies Corporation
Emeryville, California, United States